Dr. Alan Moloff Introduces Pyng Medical's Sternal IO Clinical Review Paper to Emergency Physicians at the 2015 ACEP Scientific Assembly

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 22, 2015) - Pyng Medical Corp. (TSX VENTURE:PYT), will attend the American College of Emergency Physicians 2015 Scientific Assembly taking place October 26 - 29, 2015 in Boston.

At Pyng Medical's Booth #360, Dr. Alan Moloff will demonstrate the FASTResponder Sternal Intraosseous (IO) Infusion Device and share with Emergency Physicians the results of his recent Sternal IO Clinical Review Paper.

In this paper, Dr. Moloff reviews four independent studies that focus on the importance of getting critical medications into the central circulation faster, and in higher concentration, during cardiac arrest and how, when it comes to Intraosseous (IO) Infusion, the sternal approach was shown to accomplish this significantly better than when approaching IO though the tibia.

Some quotes from the studies include:

• Study #1 - Hoskins, Stephen L, et al: "Based on the present data, we recommend that sternal IO route be considered as the first choice of drug delivery during CPR when IV access has not been established…"

• Study #2 - Pasley, Jason, et al: "...the sternal IO site provided the highest flow rates compared with the humeral and tibial insertion sites. The sternal site was also associated with a 100% success rate for initial placement facilitated by its consistent anatomy."

• Study #3: Burgert, James, et al: "There may also be a relationship between the anatomical location of the IO device and serum drug concentrations; the more distal the IO infusion site is from the sampling site, the longer concentrations of drug take to rise."

Emergency physicians can try the FASTResponder Sternal IO device for themselves and request a copy of the clinical review paper and discuss the results with Dr. Moloff at Pyng Medical's booth. The paper can also be downloaded now at go.pyng.com/ACEP.

Also at Pyng Medical's booth, Emergency Physicians can try the T-PODResponder Pelvic Stabilization Device and MATResponder and MATResponder Elite Tourniquets.

For more information, visit www.pyng.com.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements:

This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.